Although immune checkpoint inhibitors have improved cancer outcomes, their use can trigger autoimmune toxicities affecting essentially any organ system. In the cardiovascular system, these immune-related adverse events can manifest as myocarditis, pericarditis, accelerated atherosclerosis, vasculitis, arrhythmias, and...
Kerry L. Reynolds, A.-C. Villani, Z. Drobni et al.· JACC CardioOncology· 0 citations
Background The programmed cell death-1 (PD-1)/programmed cell death-ligand-1 (PD-L1) pathway is affected in immune checkpoint inhibitor (ICI)-associated acute myocarditis (AM), while this pathway in non-ICI-associated lymphocytic AM (LAM) is unexplored. Objectives This study aimed to assess cardiac levels of PD-L1/PD-1...
E. Ammirati, G. Gallone, Giacomo Veronese et al.· JACC: Advances· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.